Cargando…

Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study

INTRODUCTION: Trastuzumab plus chemotherapy is the standard first-line regimen in HER2 positive advanced gastric cancer (AGC), but lack of data in post-progression treatment. So, it is worth evaluating the efficacy of continuing trastuzumab after failure of the first-line trastuzumab based treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qian, Jiang, Huiqin, Li, Hong, Xu, Ruihua, Shen, Lin, Yu, Yiyi, Wang, Yan, Cui, Yuehong, Li, Wei, Yu, Shan, Liu, Tianshu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226611/
https://www.ncbi.nlm.nih.gov/pubmed/27409420
http://dx.doi.org/10.18632/oncotarget.10456
_version_ 1782493678285094912
author Li, Qian
Jiang, Huiqin
Li, Hong
Xu, Ruihua
Shen, Lin
Yu, Yiyi
Wang, Yan
Cui, Yuehong
Li, Wei
Yu, Shan
Liu, Tianshu
author_facet Li, Qian
Jiang, Huiqin
Li, Hong
Xu, Ruihua
Shen, Lin
Yu, Yiyi
Wang, Yan
Cui, Yuehong
Li, Wei
Yu, Shan
Liu, Tianshu
author_sort Li, Qian
collection PubMed
description INTRODUCTION: Trastuzumab plus chemotherapy is the standard first-line regimen in HER2 positive advanced gastric cancer (AGC), but lack of data in post-progression treatment. So, it is worth evaluating the efficacy of continuing trastuzumab after failure of the first-line trastuzumab based treatment. METHODS: 59 patients were enrolled from Zhongshan Hospital Fudan University, Sun Yat-sen University Cancer Center and Peking University Cancer Hospital between September 2012 and Oct 2015. Patients were divided into two groups according to the second line regimens: with or without trastuzumab. The primary endpoint was progression free survival of second line therapy (PFS2). Secondary end points included overall survival (OS), response rate, and adverse events (AEs). RESULTS: Baseline factors were well balanced between two groups. 32 patients treated with trastuzumab plus second line chemotherapy (group A) and 27 patients received chemotherapy alone (group B). The median follow-up time was 7.60 months (range 1.50-32.50). Longer median PFS2 was observed in group A than in group B (3.1 vs 2.0 months, P=0.008). There was no significant differences of median OS2 calculating from the second line therapy (10.5 vs 6.5 months, P=0.172) between two groups. Response rate was 9.3% in group A compared with 3.7% in group B (P=0.617). AEs were similar in two groups including cardiac safety. Subgroup analysis showed that factors of male, age<65, good performance status, HER2 immunohistochemical (IHC) 2+ and poor response to first line indicated superior PFS2 in patients continuing trastuzumab to those treated with chemotherapy alone. CONCLUSION: Continuing treatment of trastuzumab beyond first line therapy progression showed effective and safe in AGC.
format Online
Article
Text
id pubmed-5226611
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-52266112017-01-18 Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study Li, Qian Jiang, Huiqin Li, Hong Xu, Ruihua Shen, Lin Yu, Yiyi Wang, Yan Cui, Yuehong Li, Wei Yu, Shan Liu, Tianshu Oncotarget Clinical Research Paper INTRODUCTION: Trastuzumab plus chemotherapy is the standard first-line regimen in HER2 positive advanced gastric cancer (AGC), but lack of data in post-progression treatment. So, it is worth evaluating the efficacy of continuing trastuzumab after failure of the first-line trastuzumab based treatment. METHODS: 59 patients were enrolled from Zhongshan Hospital Fudan University, Sun Yat-sen University Cancer Center and Peking University Cancer Hospital between September 2012 and Oct 2015. Patients were divided into two groups according to the second line regimens: with or without trastuzumab. The primary endpoint was progression free survival of second line therapy (PFS2). Secondary end points included overall survival (OS), response rate, and adverse events (AEs). RESULTS: Baseline factors were well balanced between two groups. 32 patients treated with trastuzumab plus second line chemotherapy (group A) and 27 patients received chemotherapy alone (group B). The median follow-up time was 7.60 months (range 1.50-32.50). Longer median PFS2 was observed in group A than in group B (3.1 vs 2.0 months, P=0.008). There was no significant differences of median OS2 calculating from the second line therapy (10.5 vs 6.5 months, P=0.172) between two groups. Response rate was 9.3% in group A compared with 3.7% in group B (P=0.617). AEs were similar in two groups including cardiac safety. Subgroup analysis showed that factors of male, age<65, good performance status, HER2 immunohistochemical (IHC) 2+ and poor response to first line indicated superior PFS2 in patients continuing trastuzumab to those treated with chemotherapy alone. CONCLUSION: Continuing treatment of trastuzumab beyond first line therapy progression showed effective and safe in AGC. Impact Journals LLC 2016-07-07 /pmc/articles/PMC5226611/ /pubmed/27409420 http://dx.doi.org/10.18632/oncotarget.10456 Text en Copyright: © 2016 Li et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Clinical Research Paper
Li, Qian
Jiang, Huiqin
Li, Hong
Xu, Ruihua
Shen, Lin
Yu, Yiyi
Wang, Yan
Cui, Yuehong
Li, Wei
Yu, Shan
Liu, Tianshu
Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study
title Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study
title_full Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study
title_fullStr Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study
title_full_unstemmed Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study
title_short Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study
title_sort efficacy of trastuzumab beyond progression in her2 positive advanced gastric cancer: a multicenter prospective observational cohort study
topic Clinical Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226611/
https://www.ncbi.nlm.nih.gov/pubmed/27409420
http://dx.doi.org/10.18632/oncotarget.10456
work_keys_str_mv AT liqian efficacyoftrastuzumabbeyondprogressioninher2positiveadvancedgastriccanceramulticenterprospectiveobservationalcohortstudy
AT jianghuiqin efficacyoftrastuzumabbeyondprogressioninher2positiveadvancedgastriccanceramulticenterprospectiveobservationalcohortstudy
AT lihong efficacyoftrastuzumabbeyondprogressioninher2positiveadvancedgastriccanceramulticenterprospectiveobservationalcohortstudy
AT xuruihua efficacyoftrastuzumabbeyondprogressioninher2positiveadvancedgastriccanceramulticenterprospectiveobservationalcohortstudy
AT shenlin efficacyoftrastuzumabbeyondprogressioninher2positiveadvancedgastriccanceramulticenterprospectiveobservationalcohortstudy
AT yuyiyi efficacyoftrastuzumabbeyondprogressioninher2positiveadvancedgastriccanceramulticenterprospectiveobservationalcohortstudy
AT wangyan efficacyoftrastuzumabbeyondprogressioninher2positiveadvancedgastriccanceramulticenterprospectiveobservationalcohortstudy
AT cuiyuehong efficacyoftrastuzumabbeyondprogressioninher2positiveadvancedgastriccanceramulticenterprospectiveobservationalcohortstudy
AT liwei efficacyoftrastuzumabbeyondprogressioninher2positiveadvancedgastriccanceramulticenterprospectiveobservationalcohortstudy
AT yushan efficacyoftrastuzumabbeyondprogressioninher2positiveadvancedgastriccanceramulticenterprospectiveobservationalcohortstudy
AT liutianshu efficacyoftrastuzumabbeyondprogressioninher2positiveadvancedgastriccanceramulticenterprospectiveobservationalcohortstudy